<DOC>
	<DOCNO>NCT02102750</DOCNO>
	<brief_summary>The purpose study examine preservative free tafluprost ophthalmic solution ( 0.0015 % ) distribute blood circulation ocular administration child glaucoma elevate intraocular pressure . Tolerance drug safety general also assess .</brief_summary>
	<brief_title>A Study Evaluate Pharmacokinetics Tafluprost Ophthalmic Solution ( 0.0015 % ) Pediatric Patients With Glaucoma Ocular Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Glaucoma</mesh_term>
	<mesh_term>Ocular Hypertension</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<criteria>Patient nonsmoking male female ≤ 17 year age day sign informed consent . Infants must least 1 month age A diagnosis primary secondary pediatric glaucoma ocular hypertension one eye A history IOP great equal 22 mmHg least one eye . Newly diagnose patient may criterion fulfil prestudy visit . Patient currently prescribe ocular hypotensive medication accord investigator 's judgement may discontinue use least day Day 1 visit , patient treatmentnaïve ( never use use ocular hypotensive medication ) . Female patient reproductive potential must demonstrate negative pregnancy test prestudy visit Patient judge good health , glaucoma ocular hypertension , base medical history , physical examination , vital sign measurement , laboratory safety test perform prestudy visit and/or prior administration initial dose study drug Patient clinically significant abnormality electrocardiogram ( ECG ) perform prestudy visit Parent/legal guardian and/or patient have/has provide write informed consent ( accord exist local regulation ) patient assent give applicable . The patient parent/guardian agree comply study restriction , treatment plan , procedures keep schedule clinic visit . Patient currently wear continuous wear contact lens ( use daily wear contact lenses study permit ) Onesighted monocular patient , include patient dosed eye reason History goniotomy trabeculotomy within 1 month prestudy visit history cataract surgery , laser surgery , filtration surgery , implant surgery cyclodestructive surgery within 3 month prior prestudy visit one eye . Patient history evidence significant ocular trauma within 3 month prestudy visit Patient history evidence recent ocular inflammation and/or infection within 1 month prestudy visit Patient chronic conjunctivitis , chronic keratitis lacrimal deficiency Patient pregnant , breastfeeding , expect conceive within project duration study Patient major ( nonocular ) surgery , loss &gt; 5 cc/kg blood within 4 week prestudy visit Any ocular , systemic psychiatric disease/condition laboratory abnormality History febrile illness within 5 day prior start study treatment Patient history hypersensitivity component tafluprost eye drop , know severe serious hypersensitivity prostaglandin analogue product ( e.g . latanoprost ) Patient history multiple and/or severe allergy anaphylactic reaction significant intolerability prescription nonprescription ( overthecounter ) drug food There concern investigator regard safe participation patient study Current participation another clinical trial involve investigational drug/device , participation trial within last 30 day prestudy visit</criteria>
	<gender>All</gender>
	<minimum_age>1 Month</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>